Drug interactions
Dabrafenib + Empagliflozin-linagliptin
Severity: Moderate
Dabrafenib and Empagliflozin-linagliptin: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Dabrafenib induces CYP3A4 and P-gp and may lower linagliptin exposure, reducing glycemic efficacy. Dabrafenib may also cause hyperglycemia itself.
What this interaction means in plain words
Dabrafenib and Empagliflozin-linagliptin can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Dabrafenib belongs to Oncology; Empagliflozin-linagliptin belongs to Endocrine.
Why it happens
Dabrafenib induces CYP3A4 and P-gp, increasing linagliptin elimination.
What to do
Monitor blood glucose and HbA1c and adjust antidiabetic therapy if control worsens.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Dabrafenib and Empagliflozin-linagliptin, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Empagliflozin-linagliptin
Other interactions of Dabrafenib
Frequently asked questions
Can I take Dabrafenib with Empagliflozin-linagliptin?
MediHelp rates the interaction as moderate. Dabrafenib and Empagliflozin-linagliptin can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Dabrafenib induces CYP3A4 and P-gp and may lower linagliptin exposure, reducing glycemic efficacy. Dabrafenib may also cause hyperglycemia itself.
How serious is the interaction between Dabrafenib and Empagliflozin-linagliptin?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood glucose and HbA1c and adjust antidiabetic therapy if control worsens.
What other medicines interact with Empagliflozin-linagliptin?
MediHelp also lists interactions of Empagliflozin-linagliptin with, for example, Fosphenytoin, Rifampin, Rifapentine. The full list is on the Empagliflozin-linagliptin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
